Currently only small numbers of ASCVD patients achieve target LDL-c levels due to certain issues surrounding lipid lowering therapy. Prof. John Kastelein discusses the role of PCSK9 inhibition and future perspectives on lipid lowering.

Download the meeting impression of this PACE symposium during ESC 2018, which reviewed PCSK9 inhibition with regard to science, outcomes and guidance.

This is a summary of the presentation by John Kastelein, in which he discusses targeting PCSK9 in clinical practice, focusing on issues surrounding prescription of PCSK9 monoclonal antibodies.

This is a summary of the presentation by Jennifer Robinson, in which she explains that the greatest benefit of PCSK9 antibodies can be obtained at higher LDL-c levels, as seen in high-risk populations.

This is a summary of the presentation by Brian Ference, in which he shows data suggesting that PCSK9 inhibitors and statins have biologically and therapeutically equivalent effects on the risk of CVD.

Prof. Jennifer Robinson illustrates the importance of baseline LDL-c levels in CV risk reduction with PCSK9 inhibitors and explains which patients should get this treatment.

Prof. Ference shows that PCSK9 inhibition has biologically and therapeutically equivalent effects on the risk of CVD as observed with statins.

Slides as educational service to PACE members and meeting participants

Slides as educational service to PACE members and meeting participants

Slides as educational service to PACE members and meeting participants